Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-010 plus lenalidomide and rituximab in relapsed/refractory DLBCL and indolent NHL
CTR20220132Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor, lenalidomide, rituximab in diffuse large B-cell lymphoma (DLBCL), mature B-cell lymphoma, follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), sponsored by Karyopharm Therapeutics Inc.. Started May 2022; status: terminated.
02
Drugs
selinexorlenalidomiderituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on CTR20220132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220132.